Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor

Molecular Cancer Therapeutics

Volumn 5, Issue 4, 2006, Pages 995-1006

  Albert, Daniel H ^a   Tapang, Paul ^a   Magoc, Terrance J ^a   Pease, Lori J ^a   Reuter, David R ^a   Wei, Ru Qi ^a   Li, Junling ^a   Guo, Jun ^a   Bousquet, Peter F ^a   Ghoreishi Haack, Nayereh S ^a   Wang, Baole ^a   Bukofzer, Gail T ^a   Wang, Yi Chun ^a   Stavropoulos, Jason A ^a   Hartandi, Kresna ^a   Niquette, Amanda L ^a   Soni, Nirupama ^a   Johnson, Eric F ^a   McCall, J Owen ^a   Bouska, Jennifer J ^a   Luo, Yanping ^a   Donawho, Cherrie K ^a   Dai, Yujia ^a   Marcotte, Patrick A ^a   Glaser, Keith B ^a   Michaelides, Michael R ^a   Davidsen, Steven K ^a   more..

^a ABBOTT LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABT 869; ANTINEOPLASTIC AGENT; FLT3 LIGAND; N [4 (3 AMINO 1H INDAZOL 4 YL)PHENYL] N1 (2 FLUORO 5 METHYLPHENYL) UREA; PLATELET DERIVED GROWTH FACTOR; PROTEIN SERINE THREONINE KINASE; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; SUNITINIB; UNCLASSIFIED DRUG; VASCULOTROPIN; VATALANIB;

ANGIOGENESIS; ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; AREA UNDER THE CURVE; ARTICLE; BREAST CANCER; CANCER INHIBITION; CELL PROLIFERATION; COLON CANCER; DRUG ACTIVITY; DRUG EFFECT; DRUG EFFICACY; DRUG STRUCTURE; EDEMA; ENDOTHELIUM CELL; HUMAN; HUMAN TISSUE; IC 50; LEUKEMIA; LUNG SMALL CELL CANCER; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TUMOR VOLUME; XENOGRAFT;

3T3 CELLS; ANIMALS; CELL CYCLE; CELL DIVISION; CORNEA; EDEMA; ENZYME INHIBITORS; FEMALE; INDAZOLES; MICE; NEOVASCULARIZATION, PHYSIOLOGIC; PHENYLUREA COMPOUNDS; PHOSPHORYLATION; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTORS, PLATELET-DERIVED GROWTH FACTOR; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RETINAL VESSELS; UTERUS;

EID: 33646586669     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-05-0410     Document Type: Article

References (65)

1. Hunter T. Signaling: 2000 and beyond. Cell 2000;100:113-27.
2. Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S. The protein kinase complement of the human genome. Science 2002;298: 1912-34.
3. Robinson DR, Wu YM, Lin SF. The protein tyrosine kinase family of the human genome. Oncogene 2000;19:5548-57.
4. Blume-Jensen P, Hunter T. Oncogenic kinase signalling. Nature 2001; 411:355-65.
5. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-42.
6. Stirewalt DL, Radich JP. The role of FLT3 in haematopoietic malignancies. Nat Rev Cancer 2003;3:650-65.
7. Armstrong SA, Kung AL, Mabon ME, et al. Inhibition of FLT3 in MLL. Validation of a therapeutic target identified by gene expression based classification. Cancer Cell 2003;3:173-83.
8. Nakao M, Yokota S, Iwai T, et al. Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. Leukemia 1996;10:1911-8.
9. Sawyers CL. Finding the next Gleevec: FLT3 targeted kinase inhibitor therapy for acute myeloid leukemia. Cancer Cell 2002;1:413-5.
10. Levis M, Small D. FLT3: ITDoes matter in leukemia. Leukemia 2003; 17:1738-52.
11. Kottaridis PD, Gale RE, Linch DC. Flt3 mutations and leukaemia. Br J Dermatol 2003;122:523-38.
12. Lux ML, Rubin BP, Biase TL, et al. KIT extracellular and kinase domain mutations in gastrointestinal stromal tumors. Am J Pathol 2002;156: 791-5.
13. Sommer G, Agosti V, Ehlers I, et al. Gastrointestinal stromal tumors in a mouse model by targeted mutation of the Kit receptor tyrosine kinase. Proc Natl Acad Sci U S A 2003;100:6706-11.
14. Akin C, Brockow K, D'Ambrosio C, et al. Effects of tyrosine kinase inhibitor STI571 on human mast cells bearing wild-type or mutated c-Kit. Exp Hematol 2003;31:686-92.
15. Yoshiji H, Harris SR, Thorgeirsson UP. Vascular endothelial growth factor is essential for initial but not continued in vivo growth of human breast carcinoma cells. Cancer Res 1997;57:3924-8.
16. Relf M, LeJeune S, Scott PA, et al. Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer Res 1997;57:963-9.
17. Taylor AP, Osorio L, Craig R, et al. Tumor-specific regulation of angiogenic growth factors and their receptors during recovery from cytotoxic therapy. Clin Cancer Res 2002;8:1213-22.
18. Bergers G, Javaherian K, Lo KM, Folkman J, Hanahan D. Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. Science 1999;284:808-12.
19. Viloria-Petit A, Crombet T, Jothy S, et al. Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis. Cancer Res 2001;61:5090-101.
20. Cao R, Brakenhielm E, Pawliuk R, et al. Angiogenic synergism, vascular stability and improvement of hind-limb ischemia by a combination of PDGF-BB and FGF-2. Nat Med 2003;9:604-13.
21. Carmeliet P. Angiogenesis in health and disease. Nat Med 2003;9:653-60.
22. Benjamin LE, Golijanin D, Itin A, Pode D, Keshet E. Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J Clin Invest 1999;103:159-65.
23. Richardson TP, Peters MC, Ennett AB, Mooney DJ. Polymeric system for dual growth factor delivery. Nat Biotechnol 2001;19:1029-34.
24. Bergers G, Song S, Meyer-Morse N, Bergsland E, Hanahan D. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest 2003;111:1287-95.
25. Gerber H-P, Ferrara N. The role of VEGF in normal and neoplastic hematopoiesis. J Mol Med 2003;81:20-31.
26. Cheng JD, Weiner LM. Tumors and their microenvironments: tilling the soil: commentary re: A. M. Scott et al., A phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer. Clin Cancer Res 2003;9:1639-47.
27. Clin Cancer Res 2003;9:1590-5.
28. Kunz-Schughart LA, Knuechel R. Tumor-associated fibroblasts (part I): active stromal participants in tumor development and progression? Histol Histopathol 2002;17:599-621.
29. Seljelid R, Jozefowski S, Sveinbjornsson B. Tumor stroma. Anticancer Res 1999;19:4809-22.
30. Camps JL, Chang SM, Hsu TC, et al. Fibroblast-mediated acceleration of human epithelial tumor growth in vivo. Proc Natl Acad Sci U S A 1990; 87:75-9.
31. Luttun A, Tjwa M, Moons L, et al. Revascularization of ischemic tissues by PIGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1. Nat Med 2002;8:831-40.
32. Pei XH, Nakanishi Y, Takayama K, Bai F, Hara N. Granulocyte, granulocyte-macrophage, and macrophage colony-stimulating factors can stimulate the invasive capacity of human lung cancer cells. Br J Cancer 1999;79:40-6.
33. Yong LC, The mast cell: origin, morphology, distribution, and function. Exp Toxicol Pathol 1997;49:409-24.
34. Coussens LM, Raymond WW, Bergers G, et al. Inflammatory mast cells up-regulate angiogenesis during squamous epithelial carcinogenesis. Genes Dev 1999;13:1382-97.
35. Martinelli G, Piccaluga PP, Lo Coco F. FLT3 inhibition as tailored therapy for acute myeloid leukemia. Haematologica 2003;88:4-8.
36. Grundler R, Thiede C, Miething C, Steudel C, Peschel C, Duyster J. Sensitivity toward tyrosine kinase inhibitors varies between different activating mutations of the FLT3 receptor. Blood 2003;102:646-51.
37. Murata K, Kumagai H, Kawashima T, et al. Selective cytotoxic mechanism of GTP-14564, a novel tyrosine kinase inhibitor in leukemia cells expressing a constitutively active Fms-like tyrosine kinase 3 (FLT3). J Biol Chem 2003;278:32892-8.
38. Hyodo I, Doi T, Endo H, et al. Clinical significance of plasma vascular endothelial growth factor in gastrointestinal cancer. Eur J Cancer 1998;34:2041-5.
39. Obermair A, Kucera E, Mayerhofer K, et al. Vascular endothelial growth factor (VEGF) in human breast cancer: correlation with disease-free survival. Int J Cancer 1997;74:455-8.
40. Dai Y, Davidsen SK, Ericsson AM, Hartandi K, Ji Z, Michaelides MR. Indazole and benzisoxazole kinase inhibitors. U.S. Patent US 2004/ 0235892, Abbott Laboratories; 2003.
41. Freddo J, Hu-Lowe D, Pithavala YK, Steinfeldt H. Dosage forms and methods of treatment using VEGFR inhibitors. U.S. Patent US 2004/ 0224988, Agouron Pharmaceuticals, Inc.; 2004.
42. Lee SH, Lopes de Menezes D, Vora J, et al. In vivo target modulation and biological activity of CHIR-258, a multitargeted growth factor receptor kinase inhibitor, in colon cancer models. Clin Cancer Res 2005;11:3633-41.
43. Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004;64:7099-109.
44. Sun L, Liang C, Shirazian S, et al. Discovery of 5-[5-fluoro-2-oxo-1,2- dihydroindol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor tyrosine kinase. J Med Chem 2003;46:1116-9.
45. Wood JM, Bold G, Buchdunger E, et al. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res 2000;60:2178-89.
46. Kolb AJ, Kaplita PV, Hayes DJ, et al. Tyrosine kinase assays adapted to homogeneous time-resolved fluorescence. Drug Discovery Today 1998;3:333-42.
47. Luo Y, Smith RA, Guan R, et al. Pseudosubstrate peptides inhibit Akt and induce cell growth inhibition. Biochemistry 2004;43:1254-63.
48. Guo J, Marcotte P, McCall JO, et al. Inhibition of phosphorylation of the colony-stimulating factor-1 receptor (c-Fms) tyrosine kinase in transfected cells by ABT-869 and other tyrosine kinase inhibitors. Mol Cancer Ther 2006;5:1007-13.
49. Ma W, Tan J, Matsumoto H, et al. Adult tissue angiogenesis: evidence for negative regulation by estrogen in the uterus. Mol Endocrinol 2001;15:1983-92.
50. Sepp-Lorenzino L, Rands E, Mao X, et al. A novel orally bioavailable inhibitor of kinase insert domain-containing receptor induces antiangiogenic effects and prevents tumor growth in vivo. Cancer Res 2004;64:751-6.
51. Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989;246:1306-9.
52. Yee KWH, O'Farrell A-M, Smolich BD, et al. SU5416 and SU5614 inhibit kinase activity of wild-type and mutant FLT3 receptor tyrosine kinase. Blood 2002;100:2941-9.
53. Sengupta K, Banerjee S, Saxena N, Banerjee SK. Estradiol-induced vascular endothelial growth factor-A expression in breast tumor cells is biphasic and regulated by estrogen receptor-alpha dependent pathway. Int J Oncol 2003;22:609-14.
54. Bold G, Frei J, Furet P, et al. CGP 79787D (PTK787/ZK222584), CGP 84738 NVP-AAC789, NVP-AAD777 and related 1-anilino-(4-pyridylme-thyl)phthalazines as inhibitors of VEGF- and bFGF-induced angiogenesis. Drugs Future 2002;27:43-55.
55. Mukhopadhyay D, Tsiokas L, Sukhatme VP. High cell density induces vascular endothelial growth factor expression via protein tyrosine phosphorylation. Gene Expr 1998;7:53-60.
56. Kubota S, Mitsudomi T, Yamada Y. Invasive human fibrosarcoma DNA mediated induction of a 92 kDa gelatinase/type-IV collagenase leads to an invasive phenotype. Biochem Biophys Res Commun 1991;181:1539-47.
57. Abrams TJ, Lee LB, Murray LJ, Pryer NK, Cherrington JM. SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol Cancer Ther 2003;2:471-8.
58. Marxsen JH, Schmitt O, Metzen E, Jelkmann W, Hellwig-Burgel T. Vascular endothelial growth factor gene expression in the human breast cancer cell line MX-1 is controlled by 02 availability in vitro and in vivo. Ann Anat 2001;183:243-9.
59. Supuran C, Scozzafava A. Protein tyrosine kinase inhibitors as anticancer agents. Expert Opinion on Therapeutic Patents 2004;14:35-53.
60. Rini BI, Small EJ. Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma. J Clin Oncol 2005;23:1028-43.
61. Mazitschek R, Giannis A. Inhibitors of angiogenesis and cancer-related receptor tyrosine kinases. Curr Opin Chem Biol 2004;8:432-41.
62. Motzer RJ, Rini BI, Michaelson MD, et al. Phase 2 trials of SU11248 show antitumor activity in second-line therapy for patients with metastatic renal cell carcinoma (RCC). 2005 ASCO Annual Meeting 2005;4508.
63. Sebolt-Leopold JS, Merriman R, Klohs W, et al. Highly selective kinase inhibitors: too much of a good thing [abstract PL0401]? Clin Cancer Res Suppl 2003;9:6267-8S.
64. Manning WC, Bello CL, Deprimo SE, et al. Pharmacokinetic and pharmacodynamic evaluation of SU11248 in a phase I clinical trial of patients (pts) with imatinib-resistant gastrointestinal stromal tumor (GIST) [abstract 768]. Proc Am Soc Clin Oncol 2003;22:192.
65. Inai T, Mancuso M, Hashizume H, et al. Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts. Am J Pathol 2004;165:35-52.